This site is for Canadian Healthcare Professionals.

restonsFORTSrestonsFORTS

Your patients have moved on from COVID‑19.

Let's help keep it that way.

Spikevax DASH Document
Share this site

Spikevax is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.1

restonsFORTS

COVID-19 is still active in Canada

Like other respiratory viruses, COVID-19 is still circulating.2 Some individuals may only experience asymptomatic to mild disease, others – particularly those with increasing age – continue to be at increased risk for severe illness.3

View the latest COVID-19 Surveillance Report

Identifying patients at increased risk for severe COVID-19 infection3-5*

While anyone can be infected, some populations are at increased risk for SARS-CoV-2 exposure and/or severe COVID-19 disease and outcomes. For some patients, risks factors may overlap – further increasing their overall risk.3–5

Increased risk of exposure3,4
Increased risk of severe disease3–5
Situational Factors
e.g., congregate living (long-term care homes or other congregate living settings); occupational settings (healthcare workers or other care providers in facilities or community settings)†
Biological factors
e.g., aged ≥65 years; underlying medical conditions†

Social factors

e.g., socioeconomic status; belonging to a racialized population (First Nations, Inuit and Métis communities or other equity-denied communities)†

Underlying medical conditions associated with severe COVID-19 disease according to PHAC and NACI4,5

Think C•O•V•I•D to help recall at-risk medical conditions4,5

C

CANCER & CHRONIC DISEASE

  • Cancer
  • Chronic disease (kidney disease; liver diseases [cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis]; lung diseases [bronchiectasis, COPD, ILD, pulmonary hypertension, PE]; cystic fibrosis; diabetes mellitus, [types 1 and 2]; heart conditions [e.g., cardiomyopathies, HF]; smoking [current or former])

O

OBESITY & OBSTETRICS

  • Obesity (BMI ≥30 kg/m2)
  • Pregnancy and recent pregnancy

V

VASCULAR DISEASE & VULNERABILITIES

  • Vascular disease (coronary artery disease; cerebrovascular disease)
  • Medical and/or social vulnerabilities (e.g., people who use substances regularly; persons experiencing homelessness or who are unhoused)

I

INFECTION & IMMUNO-COMPROMISED

  • Infection (HIV; tuberculosis)
  • Immunocompromised (primary immunodeficiency diseases; solid organ or blood stem cell transplant); immunosuppressive medications (e.g., corticosteroids)

D

DISABILITIES & DISORDERS

  • Disabilities (e.g., Down syndrome, learning, intellectual, or developmental disabilities; ADHD; cerebral palsy; congenital disabilities; spinal cord injuries)
  • Mental health disorders (mood disorders, e.g., depression; schizophrenia spectrum disorders)

Adapted from NACI and PHAC (2025).4,5

COPD=chronic obstructive pulmonary disease; ILD=interstitial lung disease; PE=pulmonary embolism; HF=heart failure; BMI=body mass index; ADHD=attention-deficit/hyperactivity disorder; NACI=National Advisory Committee on Immunization; PHAC=Public Health Agency of Canada.
* The effectiveness and safety of Spikevax in at-risk populations has not been evaluated in clinical trials.
† Those individuals aged ≥6 months.

Still recommended for eligible patients.4


Now available in two convenient formats.1

The Spikevax (COVID-19 mRNA vaccine) formulation remains available for eligible patients for Fall 2025 vaccination – and is now available in a Canadian-made pre-filled syringe.

NACI guidance on the use of COVID-19 vaccines for 2025 to summer 20264*

STRONG recommendation

WHO SHOULD RECEIVE ≥1 DOSE OF COVID-19 VACCINE

Previously vaccinated and unvaccinated individuals at increased risk of SARS-CoV-2 exposure or severe COVID-19 disease, including:

All adults aged ≥65 years

Those aged ≥6 months who:

reside in congregate living settings or long-term care homes
are pregnant
are healthcare workers or care providers in facilities and community settings
are with underlying medical conditions, including children with complex needs†
are in or from First Nations, Inuit, and Métis communities†
are members of racialized or equity-denied communities

DISCRETIONARY recommendation

WHO MAY RECEIVE COVID-19 VACCINE

All other previously vaccinated and unvaccinated individuals (aged ≥6 months) who are not at increased risk for SARS-CoV-2 exposure or severe COVID-19 disease

Vaccination timing & considerations

  • For previously vaccinated individuals, the minimum interval between COVID-19 doses is 3 months
  • When deciding on the best time to get vaccinated, individuals may consider factors such as:
    • time since their last dose
    • test-confirmed SARS-CoV-2 infection
    • local virus circulation
    • personal circumstances (e.g., travel, significant medical procedures, large gatherings)

For the full statement, consult the Guidance on the use of COVID-19 vaccines for 2025 to summer 2026.

* Provincial/territory criteria may vary. Refer to your regional health authority for complete eligibility criteria.
† There is limited evidence on clinical risk factors for severe COVID-19 disease in pediatric populations. Children at increased risk for severe outcomes may include children who are medically fragile/have medical complexities, children with more than one comorbidity, children with neurological disorders, children with chronic lung disease, and children with Down syndrome (Trisomy 21), and other immunocompromising conditions.
‡ Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples Act.

COVID-19 vaccine programs by province/territory: summary of 2025/26 eligibility criteria

To view the 2025/26 eligibility criteria for your area, please select from the list of provinces and territories.
 
Important: eligibility criteria may change at undefined times. Always consult with your regional health authority for the latest information.

Select an area

Eligibility Summary

Select a province to see eligibility criteria

We're here to help!

Please contact us if you have any questions about ordering and product availability or to arrange an appointment with our field staff.

Email

WeCare@modernatx.com

Phone

1-866-MODERNA (1-866-663-3762)8:00 AM - 8:00 PM ETMonday - Friday (closed holidays)

Prescribing Information

Indication and clinical use:

Spikevax® (COVID-19 mRNA vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

Pediatrics: Safety and efficacy in individuals <6 months of age has not yet been.

Contraindication:

  • Hypersensitivity to the active ingredient or to any ingredients in the formulation, including any non-medicinal ingredient, or component of the container.

Relevant warnings and precautions:

  • Hypersensitivity and anaphylaxis
  • Myocarditis and pericarditis
  • Patients with acute infection
  • Patients with hematologic disorders or on anticoagulant therapy
  • Patients who are immunocompromised
  • Syncope
  • Vaccination with Spikevax may not protect all recipients

For more information:

Consult the Product Monograph at spikevaxpro.com/pm for important information regarding adverse reactions, drug interactions, and dosing, which have not been discussed in this piece. The Product Monograph is also available by calling us at 
1-866-MODERNA (1-866-663-3762).

References

  1. Spikevax Product Monograph. Moderna Biopharma Canada Corp.
  2. Government of Canada. Canadian respiratory virus surveillance report: COVID-19. Available at: https://health-infobase.canada.ca/respiratory-virus-surveillance/covid-19.html. Accessed September 10, 2025.
  3. Public Health Agency of Canada (PHAC). COVID-19 vaccines: Canadian Immunization Guide. Available at:
    https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html. Accessed May 12, 2025.
  4. National Advisory Committee on Immunization (NACI), An Advisory Committee Statement (ACS): Guidance on the Use of COVID-19 vaccines for 2025 to summer 2026. Published January 10, 2025.
  5. Public Health Agency of Canada (PHAC). COVID-19 signs, symptoms and severity of disease: A clinician guide.
    Available at:     https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/signs-symptoms-severity.html#a3. Accessed July 11, 2025.
  6. Alberta Health Services. COVID-19 info for Albertans. Available at: https://www.alberta.ca/coronavirus-info-for-albertans#vaccine. Accessed September 6, 2025
  7. Government of British Columbia. COVID-19 immunizations. Available at: https://www2.gov.bc.ca/gov/content/health/managing-your-health/immunizations/covid-19-immunization. Accessed September 8, 2025.
  8. Province of Manitoba. COVID-19 vaccine eligibility, vaccine schedule, and proof of vaccination. Available at: https://www.gov.mb.ca/covid19/vaccine.html. Accessed September 6, 2025.
  9. Government of Manitoba. Eligibility criteria for Manitoba’s publicly-funded immunization program. Available at: https://www.gov.mb.ca/health/publichealth/cdc/vaccineeligibility.html. Accessed October 8, 2025.
  10. Government of New Brunswick. Coronavirus (COVID-19) Vaccine. Available at: https://www2.gnb.ca/content/gnb/en/corporate/promo/vaccines-and-immunization/sars-cov-2-vaccines.html. Accessed October 3, 2025.
  11. Government of Newfoundland and Labrador. Time for the shot: COVID-19. Available at: https://www.timefortheshot.ca/covid-19/. Accessed October 8, 2025.
  12. Nova Scotia Health. COVID-19 vaccines. Available at: https://www.nshealth.ca/coronavirusvaccine. Accessed October 3, 2025.
  13. Ontario Ministry of Health. COVID-19 vaccines. Available at: https://www.ontario.ca/page/covid-19-vaccines#section-2. Accessed September 22, 2025.
  14. Government of Prince Edward Island. Flu, COVID-19, and RSV vaccination. Available at: https://www.princeedwardisland.ca/en/information/health-pei/flu-covid-19-and-rsv-vaccination. Accessed October 3, 2025.
  15. Government of Quebec. COVID-19 vaccination. Available at: https://www.quebec.ca/en/health/advice-and-prevention/vaccination/covid-19-vaccine#c233194. Accessed October 8, 2025.
  16. Government of Saskatchewan. Fall immunization program. Available at: https://www.saskatchewan.ca/residents/health/accessing-health-care-services/immunization-services/immunization-programs. Accessed October 8, 2025.
  17. Government of Yukon. Book a seasonal immunization appointment. Available at: https://yukon.ca/en/health-and-wellness/health-concerns-diseases-and-conditions/book-seasonal-immunization-appointment. Accessed October 3, 2025.

Stay up to date

Receive the latest information about all products in the Moderna pipeline.

By submitting your information, you agree to Moderna’s Terms and Conditions. You also acknowledge that your information will be processed in accordance with Moderna’s Privacy Statement. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.